Live mandate · Medical Devices
Nirvesh Enterprises
Deep-tech MedTech developing advanced medical devices across neuroscience, oncology, and cardiovascular care. Combines engineering with regulatory expertise.
Medical devices, where regulatory clearance and manufacturing quality gate every capital milestone.
MedTech sits between deep tech and manufacturing and inherits the hard parts of both. There is a long pre-revenue development cycle, and then a second gate — CDSCO clearance, quality systems, and clinical evidence — before a single unit can be sold at scale.
Capital has to be structured around those gates. Equity raised before clearance is priced against risk that clearance itself removes; grants and innovation schemes are designed precisely for that window. Getting the sequence wrong costs founders far more ownership than the round size suggests.
We work with device companies on the capital sequence, on the manufacturing and quality-system economics that follow clearance, and on the diligence pack a strategic acquirer in this sector actually reads.
How we work in MedTech
Structure grants and non-dilutive capital into the pre-clearance window so equity is priced after the risk is retired, not before.
Cost-to-serve, quality-system overhead, and margin modelling for a regulated production process.
The IP, clinical evidence, and quality documentation a device acquirer diligences first.
Capabilities
Looking for the programmes themselves? See which government grants and schemes you qualify for.
Proof
Live mandate · Medical Devices
Deep-tech MedTech developing advanced medical devices across neuroscience, oncology, and cardiovascular care. Combines engineering with regulatory expertise.
Live mandate · Digital Health
Digital health platform connecting healthcare delivery, preventive care, and wellness. Scalable tech-enabled model addressing accessibility gaps.
Tell us where the business actually is and we will tell you what we would do first. No deck required.